Atacand Hct

• Fatigue and Asthenia: A general feeling of tiredness or lack of energy.
• Hyperkalemia: Elevated levels of potassium in the blood. This is more common in patients with heart failure or underlying kidney disease. Symptoms may include muscle weakness or an irregular heartbeat.
• Hypotension: Symptomatic low blood pressure, particularly in patients who are dehydrated or taking other diuretics.
• Headache: Persistent but usually mild head pain.

Rare but documented side effects include:

• Renal Function Impairment: In susceptible individuals (e.g., those with renal artery stenosis), the drug may cause a rise in blood urea nitrogen (BUN) and serum creatinine.
• Hyponatremia: Low sodium levels in the blood, which can cause confusion or seizures if severe.
• Hematologic Changes: Rare cases of agranulocytosis (low white blood cell count) or leukopenia have been reported.

> Warning: Stop taking Candesartan Cilexetil and call your doctor immediately if you experience any of the following serious symptoms:

• Angioedema: Swelling of the face, lips, tongue, or throat, which can cause difficulty breathing or swallowing. This is a medical emergency.
• Signs of Kidney Failure: A significant decrease in urine output, swelling in the feet or ankles, or shortness of breath.
• Severe Hyperkalemia: Chest pain, palpitations, or profound muscle weakness.
• Liver Problems: Yellowing of the skin or eyes (jaundice), dark urine, or severe abdominal pain.
• Severe Allergic Reaction: Hives, skin rash, or blistering and peeling skin (Stevens-Johnson Syndrome).

Prolonged use of Candesartan Cilexetil is generally considered safe and effective for managing chronic conditions. The primary long-term concern is the potential for gradual changes in kidney function, especially in patients with pre-existing renal disease or those taking other medications that affect the kidneys (like NSAIDs). Periodic blood tests to monitor creatinine and potassium levels are standard practice for long-term therapy. Some studies have investigated the drug's effect on glucose metabolism, generally finding it to be metabolic-neutral or even slightly beneficial compared to older antihypertensives like beta-blockers.

Candesartan Cilexetil carries a Boxed Warning regarding Fetal Toxicity. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios (low amniotic fluid) can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, Candesartan Cilexetil should be discontinued as soon as possible.

Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment remains safe and effective.

• Anaphylaxis and Angioedema: There is a risk of severe allergic reactions. Patients with a history of angioedema (swelling of the deep layers of the skin) with other medications, particularly ACE inhibitors, should use Candesartan Cilexetil with caution, although the risk is lower than with ACE inhibitors.
• Renal Function Impairment: As a consequence of inhibiting the RAAS, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS (e.g., patients with severe congestive heart failure), treatment with ARBs has been associated with oliguria and/or progressive azotemia. Patients with bilateral renal artery stenosis are at particularly high risk for acute renal failure.
• Hyperkalemia: Candesartan can cause an increase in serum potassium. This risk is heightened in patients with renal impairment, diabetes mellitus, or those using potassium-sparing diuretics or potassium supplements. Regular monitoring of electrolytes is essential.
• Hypotension in Volume-Depleted Patients: In patients with an activated renin-angiotensin system, such as those receiving high doses of diuretics, symptomatic hypotension may occur. These conditions should be corrected prior to administration of Candesartan Cilexetil.

Healthcare providers will typically require the following monitoring parameters:

• Blood Pressure: Regular checks to ensure the medication is achieving the target pressure.
• Renal Function Tests: Serum creatinine and BUN levels should be checked periodically, especially in the first few weeks of therapy and after dose adjustments.
• Serum Potassium: Electrolyte panels are necessary to screen for hyperkalemia.
• Pediatric Monitoring: In children, blood pressure and renal function require close monitoring due to the developing nature of their physiological systems.

Candesartan Cilexetil may cause dizziness or fatigue, particularly at the start of treatment or when the dose is increased. Patients should observe how they react to the medication before driving, operating heavy machinery, or performing other tasks that require alertness.

Alcohol can enhance the blood pressure-lowering effect of Candesartan Cilexetil, which may lead to increased dizziness, lightheadedness, or fainting. It is generally advised to limit alcohol consumption while taking this medication.

Do not stop taking Candesartan Cilexetil abruptly. While it does not typically cause a "rebound" effect like some beta-blockers, your blood pressure will likely rise quickly once the medication is stopped, increasing your risk of cardiovascular events. If discontinuation is necessary, your doctor will provide a plan to transition to another therapy.

> Important: Discuss all your medical conditions, including any history of liver or kidney disease, with your healthcare provider before starting Candesartan Cilexetil.

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Medications like ibuprofen, naproxen, and selective COX-2 inhibitors (e.g., celecoxib) can interfere with the antihypertensive effect of Candesartan Cilexetil. Furthermore, in patients who are elderly, volume-depleted, or have compromised renal function, the co-administration of an ARB and an NSAID may result in further deterioration of renal function, including possible acute renal failure.
• Other Antihypertensives: While often used together intentionally, combining candesartan with other blood pressure medications (beta-blockers, calcium channel blockers) increases the risk of hypotension. Dosage adjustments may be required.

Candesartan Cilexetil does not have significant interactions with most foods. Unlike some other cardiovascular drugs, it does not interact with grapefruit juice. However, patients should be cautious with Salt Substitutes. Many salt substitutes contain potassium chloride instead of sodium chloride; using these while on an ARB can lead to dangerously high potassium levels.

• St. John's Wort: While not a direct metabolic interaction, some herbal supplements that affect blood pressure should be used with caution.
• Natural Licorice: Can cause sodium retention and potassium loss, potentially counteracting the effects of the medication.
• Hawthorn: May have mild antihypertensive properties and could theoretically increase the effect of candesartan.

Candesartan Cilexetil does not typically interfere with common laboratory tests, although it will obviously affect results for serum creatinine, BUN, and potassium. In rare cases, it may cause slight decreases in hemoglobin and hematocrit, but these are rarely clinically significant.

For each major interaction, the management strategy usually involves more frequent monitoring of clinical parameters (blood pressure, kidney function, electrolytes) or adjusting the dosage of one or both medications.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.

• Severe Renal Impairment: While not an absolute contraindication, patients with a GFR < 30 mL/min require very low starting doses and intensive monitoring.
• Bilateral Renal Artery Stenosis: In these patients, the drug can cause a rapid decline in kidney function because the kidneys rely on angiotensin II-mediated vasoconstriction of the efferent arteriole to maintain filtration pressure.
• Aortic or Mitral Valve Stenosis: Patients with significant valvular obstruction may be at risk for decreased coronary perfusion if their blood pressure is lowered too aggressively.
• Hyperkalemia: If a patient already has high potassium levels, starting an ARB may exacerbate the condition to dangerous levels.

Patients who have experienced angioedema while taking an ACE inhibitor (e.g., lisinopril, enalapril) may be at a slightly increased risk of experiencing angioedema with Candesartan Cilexetil. While the mechanism of angioedema differs between the two classes (ACE inhibitors involve bradykinin, while ARBs do not), clinical caution is advised. Most patients who cannot tolerate ACE inhibitors due to cough can safely take ARBs, but those with a history of airway-threatening angioedema should be evaluated carefully.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart, liver, or kidney disease, before prescribing Candesartan Cilexetil.

Of the total number of subjects in clinical studies of Atacand, approximately 21% were 65 and over, while 3% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more likely to have decreased renal function and may be taking multiple other medications (polypharmacy), increasing the risk of drug interactions and hypotension-related falls. Healthcare providers should start at the lower end of the dosing range and monitor closely.

In patients with renal impairment, serum concentrations of candesartan are increased. For those with moderate to severe impairment or those on hemodialysis, the recommended starting dose is 8 mg once daily for hypertension. Close monitoring of potassium and creatinine is mandatory. Candesartan is not dialyzable.

Patients with moderate hepatic impairment have been shown to have an increase in the AUC of candesartan by about 145%. A starting dose of 8 mg is recommended for these patients. No specific data is available for severe hepatic impairment, and use in such patients is generally discouraged unless the benefits clearly outweigh the risks.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure medication safety.

| Parameter | Value |

|---|---|

| Bioavailability | ~15% (as active candesartan) |

| Protein Binding | >99% (primarily albumin) |

| Half-life | ~9 hours |

| Tmax | 3 to 4 hours |

| Metabolism | Minimal (minor CYP2C9 activity) |

| Excretion | Renal 33%, Fecal 67% |

• Molecular Formula: C33H34N6O6
• Molecular Weight: 610.66 g/mol
• Solubility: Practically insoluble in water; sparingly soluble in methanol.
• Structure: It is a tetrazole derivative containing a benzimidazole group and a cilexetil ester moiety that facilitates oral absorption.

Candesartan Cilexetil is classified as an Angiotensin II Receptor Blocker (ARB). Other drugs in this class include losartan, valsartan, and irbesartan. Within the broader therapeutic area of antihypertensives, ARBs are considered a primary choice for patients with diabetes, chronic kidney disease, or heart failure due to their organ-protective properties.